d71daa047678ecb54c4663003055c83bbad2adf16390821549a0de427be007e2  Counter_Arguments_Master_Brief.html
a04193a2afc4829e8c08cb16a47935f57ee392676118c853dc334ee352f2e276  Execution_Roadmap.html
3a6e92fa5e6f94206b42a0560d373d9af1cc8104028581f466530deb7e04449f  Final_Recommendation.html
e30fca7ad33b959dedf272948edd17089a1362a19dc82f991bbba1ca9102476a  FTO_Analysis_Lipid_Matrix.html
ee447a0fad5057a650b4056f1950ec427070e7922ac0a7f4a3def27d613d03ce  FTO_Analysis_MUPS.html
0ddc65bbfa56a0019430d7a0ff1fba9b4208c98d5dac24d695efd48e55e176ee  IPR_Petition_Draft.html
b57f1986d594e5f5c8f568e1e6c9969848c0bddea819ee2e493de1eb27bc78fb  Lipid_Matrix_Formulation_Protocol.html
e02b9d0371fcb1786cb9841d68e12ca34d8a5fa15db8aa567628ace5db2c2469  Lipid_Matrix_Risks.html
69f5d471828a3a41de28bb8079cfee85f2597f6fe583ec0fe788fcd7e6b6c53e  Minoxidil_ER_Formulations.html
6eebde8e96defc4dbe9fd8a6b4d82eb30d9b818816addef5feb5303abe2a19c3  PK_Analysis_Patent_Differentiation.html
175380f8b92846e83423d795bc439d06eb6091de9100368ea9cbeb4098ee57ee  Release_Rate_Control_Strategies.html
8adecca35bd1c5829d2b979bd48ee32b1b0177c0bf9c769c1a48a09a3cfa5018  Technology_Precedent_Report.html
ac575b49891429e83fd662991bc378fb9f5db95431f23e4c1e99c09ee0a7e4cc  Veradermics_Counterarguments_Analysis.html
8affff2afa81c2e047690e4e6184bb9f55201d5f80abca5a627ade1d8a921369  Veradermics_Steelman_Analysis.html
ff49b3779e4ad43ebc23150f070a7fcc2f2144e3d2bfac61e8725726261867fa  Minoxidil_ER_Formulations.md
edf84b9e95fc8bb59f283d221e65216e36bf1dc313b942e1a94d0889edd1c191  README.md
